Beneficial Effects on Pregnancy Outcomes of Thyroid Hormone Replacement for Subclinical Hypothyroidism
Table 2
A comparison of pregnancy outcomes in women with and without detectable circulating thyroid antibodies.
Variable
No positive antibody
≥1 positive antibody
value
Odds ratio
LC
UC
()
()
%
%
TGAB > 60 IU/mL
0
0.0
139
58.4
N/A
0.1
0.1
0.1
TPOAb > 60 IU/mL
0
0.0
187
78.6
N/A
0.1
0.1
0.1
TSH > 2.5
46
5.8
47
19.7
0.0001
4.0
2.6
6.2
GTT positive (GD)
28
3.6
10
4.3
0.638
1.2
0.6
2.5
Nulliparous
301
38.6
79
34.2
0.226
0.8
0.6
1.1
APGAR 1 minute < 7
25
3.2
8
3.5
0.861
1.1
0.5
2.4
APGAR 5 minutes < 7
5
0.6
2
0.9
0.724
1.3
0.3
7.0
Fetal death in utero (<26 weeks)
3
0.4
2
0.9
0.371
2.2
0.4
13.4
Stillbirth or FDIU
10
1.3
4
1.7
0.628
1.3
0.4
4.3
Pregnancy induced hypertension
17
2.2
3
1.3
0.383
0.6
0.2
2.0
Premature labour
15
1.9
4
1.7
0.827
0.9
0.3
2.7
Antepartum haemorrhage
3
0.4
2
0.9
0.371
2.2
0.4
13.4
Abruption
1
0.1
0
0.0
0.583
0.8
0.7
0.9
SROM
19
2.4
1
0.4
0.052
0.2
0.0
1.3
SGA
11
1.4
7
3.0
0.110
2.1
0.8
5.6
TSH, thyroid stimulating hormone; TGAb, anti-thyroglobulin antibodies; TPOAb, thyroperoxidase antibodies; SROM, spontaneous rupture of membranes; SGA. small for gestational age; FDIU, fetal death in utero.
